104 related articles for article (PubMed ID: 38862868)
1. Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
Kitano S; Tsunashima R; Kato C; Watanabe A; Sota Y; Matsumoto S; Morita M; Sakaguchi K; Naoi Y
Breast Cancer; 2024 Jun; ():. PubMed ID: 38862868
[TBL] [Abstract][Full Text] [Related]
2. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
3. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
[TBL] [Abstract][Full Text] [Related]
5. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
6. Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
Tsunashima R; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2018 Aug; 171(1):33-41. PubMed ID: 29728801
[TBL] [Abstract][Full Text] [Related]
7. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
[TBL] [Abstract][Full Text] [Related]
8. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
[TBL] [Abstract][Full Text] [Related]
9. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Richman J; Ring A; Dowsett M; Sestak I
Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
[TBL] [Abstract][Full Text] [Related]
10. Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
Dejthevaporn T; Patanayindee P
Breast Cancer (Auckl); 2023; 17():11782234231186869. PubMed ID: 37533837
[TBL] [Abstract][Full Text] [Related]
11. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
[TBL] [Abstract][Full Text] [Related]
12. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
Lee JH; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2021; 11():691277. PubMed ID: 34239805
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
Villasco A; Accomasso F; D'Alonzo M; Agnelli F; Sismondi P; Biglia N
Breast Cancer; 2021 Sep; 28(5):1131-1140. PubMed ID: 33939116
[TBL] [Abstract][Full Text] [Related]
15. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
[TBL] [Abstract][Full Text] [Related]
16. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
17. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
18. Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
Wang C; Chen C; Lin Y; Zhou Y; Mao F; Zhu H; Zhang X; Shen S; Huang X; Wang X; Zhao B; Yang J; Sun Q
Sci Rep; 2020 Mar; 10(1):4660. PubMed ID: 32170181
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor-positive breast cancer.
Chen W; Wu J; Zhu Y; Huang J; Chen X; Huang O; He J; Li Y; Chen W; Shen K; Zhu L
Front Oncol; 2022; 12():996522. PubMed ID: 36727047
[TBL] [Abstract][Full Text] [Related]
20. Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
Tsukamoto F; Arihiro K; Takahashi M; Ito KI; Ohsumi S; Takashima S; Oba T; Yoshida M; Kishi K; Yamagishi K; Kinoshita T
BMC Cancer; 2021 Oct; 21(1):1077. PubMed ID: 34610807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
